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LETTERS TO THE EDITOR 
Nitroxide Radical Reduction in Nude Mouse Skin 
To the Editor: 
In the November issue, Fuchs et al reported on the reduction of 
spin-labels by nude mouse dermis/epidermis extracts and by the 
surface of nude mouse skin [1]. 
Two basic conclusions were reached from their studies: 1) 
dermis/epidermis extracts reduce nitroxide radicals primarily by 
ascorbic acid, and 2) epidermis contains an NADPH-dependent 
thioprotein which reduces thioredoxin, and reduced thioredoxin 
reduces nitroxide radicals. The authors conclude that this thiopro-
tein is not thioredoxin reductase but is possibly the glutathione re-
ductase/ glutaredoxin system. 
We are compelled to write this letter to the editor because several 
ques tions need to be answered regarding the interpretation of the 
data presented in the Fuchs' paper and on the misrepresentation of 
the quoted literature published by our group [2,3]. 
First, the title of the paper "Free Radical Reduction Mechanisms 
in Mouse Epidermis Skin Homogenates" is misleading because 
most of the reported experiments are performed with extracts pre-
pared from mouse dermis/epidermis, where at leas t 90% of the as-
sayed extracts would be of dermal origin; therefore, these results 
cannot be extrapolated to experiments done with epidermis alone. 
Second, the authors compare the concentration of ascorbic acid (a 
free radical reducing substrate) to concentrations of thioredoxin re-
ductase (a free radical reducing catalyst) and make the point that 
ascorbic acid has to be more important than the enzyme because 
there is more of it present in dermis/epidermis homogenate. This 
argument is very tenuous, because ascorbate as a substrate will be 
used up in reactions, but the enzyme will continuously catalyze 
radical reduction with an affinity for nitroxide radicals of Km = 
3 X 1Q-6M (4]; therefore, nitroxide radicals are excellent substrates 
with a high affinity for thioredoxin reductase (see Fig 4 in [1 ]). Also, 
the experiments with BCNU as inhibitor are invalid because this 
and other nitrosoureas inhibit thioredoxin reductase better than 
glutathione reductase. 
Third, the authors consistently refer to thioredoxin reductase as a 
flavo protein, when it is in fact a thioprotein with a disulfide active 
site. It does contain FAD as electron acceptor from NADPH, and it 
is named thioredoxin reductase because it reduces thioredoxin 
(MWT 11,400) as its natural electron acceptor. The authors claim to 
have discovered a thioprotein (yet uncharacterized) which is 
NADPH-dependent and reduces thioredoxin, but they conclude 
that this thioprotein is not thioredoxin reductase. Why not? What 
evidence is available for the reduction of thioredoxin by the gluta-
thione reductasejglutaredoxin system as the authors propose? To 
our knowledge, glutaredoxin is the electron acceptor for glutathi-
one reductase/glutathione, whereas thioredoxin serves as acceptor 
for thioredoxin reductase. These alternate electron transport path-
ways are reported now in all modern Biochemistry textbooks [5] . A 
review of the literature reveals that only thioredoxin purified from 
Anabaena (a blue-green algae) and T 4 bacteriophage can accept elec-
trons from glutathione reductase/ glutathione. There are also signif-
icant differences for the reduction of DTNB by thioredoxin reduc-
tases from different organisms. For example, the Escherichia co{i 
enzyme requires thioredoxin to reduce DTNB, but the mamma-
lian/human enzymes do not need thioredoxin for full activity. 
Fourth, they state that thioredoxin reductase has been suggested to 
play a major role in free radical reduction in the human epidermis by 
our group. It should be pointed out that we have shown directly that 
thioredoxin reductase represents 5.2% of the acid soluble protein 
fraction of human keratinocytes [ 6, 7], and that this enzyme is stereo 
selectively inhibited both on the pure enzyme and in skin biopsies 
by 13 cis retinoic acid [6] . It should be noted that the glutathione 
reductase/glutaredoxin system is not inhibited by 13 cis retinoic 
acid (6] . In addition, we have proved covalent active site inhibition 
of thioredoxin reductase by 14C azelaic acid [2] and have discovered 
a calmodulin-like EF-hands calcium binding site on this enzyme 
(4,7]. Therefore, the references to our work [2,3] do not present any 
of these findin gs; instead, the authors suggest that azelaic acid and 
calcium simply alter membrane potentials. References should not be 
quoted unless a synopsis of the actual conclusions are cited. Without 
this presentation of the facts, there is a tendency to mislead the 
readers. 
Finally, the authors claim to have synthesized our spin-label (U.S. 
Patent 4,849 ,346 [ 1989]) and have shown that it readily penetrates 
membranes, although the data in support of this are not shown. In 
1986, we published two papers [8,9] showing that our substrate does 
not penetrate cell membranes more than 10% in 1 h . These early 
publications are ignored, and it seems to us that it would be very 
important to present membrane-transport data with our spin-label 
under the 5-min duration required for experiments reported in [1] . 
How much of our spin-label is transported through epidermal 
membranes in 5 min? Why didn't the authors use our spin-label for 
their experiments, along with other specific spin-labels, so that a 
direct comparison of the results could be made between mouse and 
human skin? In the absence of any genuine comparative data, it is 
impossible to draw the conclusions presented in either the discus-
sion of thioredoxin reductase in human skin or on the efficacy of our 
patented free radical substrate assay for thioredoxin reductase. 
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REPLY 
In 1988 we w rote a letter to the Editor of the Journal of Investigative 
Dermatology ( 1J and A rchives ofDermatology (2J criticizing the validity 
of a "bioassay" developed by Schallreuter eta! for measuring thiore-
doxin reductase activity in intact epidermis. Now we would like to 
respond to criticisms raised by Schallreuter et al about our paper 
"Free Radical Reduction Mechanisms in Mouse Epidermis Skin 
Homogenates." The comments ofSchallreuter et al partially reflect 
misinterpretation of our investigations and of others on the specific-
ity of nitroxide reduction in biologic tissues. 
Despite what Schall reuter et al state in their introduction of the 
letter to the Editor, our article clearly indicates that 1) we did not 
employ dermis/epidermis extracts, but skin homogenates, and 2) 
we do not state that "epidermis contains an NADPH dependent 
thioprotein which reduces thioredoxin and reduced thioredoxin 
reduces nitroxide radicals." However, we do conclude " there is at 
least one thiol dependent mechanism in mouse epidermis that can 
reduce free radicals (nitroxides) that is distinct from thioredoxin 
reductase." W e show that it is important to distinguish between 
reduction of piperidinoxyl and pyrroline type nitroxides in biologic 
systems. We found that the main reducing activity for piperidin-
oxy!-type nitroxides in mouse skin homogenates is ascorbate, and 
we clearly point out that pyrroline type nitroxides are relatively 
inert towards ascorbate. The fact that pyrroline type nitroxides are 
slowly reduced in skin homogenates and in epidermis indicates that 
non-ascorbate mediated reducing processes are present. We con-
clude for mouse skin homogenates, but not for the epidermis, that 
"among the possible candidates for this system(s) is the glutaredoxin 
system ." 
We disagree with all major statements made by Schallreuter et a!. 
First, the title is definitely not misleading. In fact, both skin homog-
enates and intact epidermis (Figs 10 and 11) were investigated in our 
study. We have discussed in "Heterogeneity ~f Thi?redoxi~ Re-
ductase in Skin" that in skin homogenates epiderrms contnbutes 
about 4% of the total tissue mass. In our Discussion section we did 
not extrapolate results we obt~ined ~ith skin homogenates to ex-
periments done with intact epidermis. 
Second, clearly ascorbate can act as a free radical scavenging agent 
and can be recycled from its one electron oxidation product, the 
ascorbyl radical, or from its two el~ctron oxidation produc~, dehy-
droascorbate, by different mechamsms. It has been recogmzed for 
more than five decades (3J that ascorbate is regenerated from dehy-
droascorbate by a thiol dependent pathway. Although in general it 
cannot be excluded that several enzymes may be affected by BCNU 
[1,3-bis(2-chlorethyl)-1-nitrosourea), previous studies of the inacti-
vation of glutathione reductase by BCNU have shown that lt can 
be used as a selective inhibitor in isolated hepatocytes [4]. which 
possess both thioredoxin reductase and glutathione reductase activi-
ties. 
Third, we did not claim to have discovered an NADPH-depen-
dent thioprotein that reduces thioredoxin, rather we suggested that 
"there is at least one th.iol dependent mechanism in mouse epi-
dermis that can reduce free radicals" (nitroxides) "that is distinct 
from thioredoxin reductase." 
Fourth, we strongly object to their statement that we tend to 
mislead the reader. Schallreuter et a! published a synopsis of t heir 
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work on free radical reduction by thioredoxin reductase in 1989 (5]. 
In their review of their own work they suggest that the specificity of 
the thioredoxin reductase assay on the surface of epidermal cells was 
satisfied by several properties common to purified thioredoxin re-
ductase and to the enzyme in epidermis. Isolated thioredoxin reduc-
tase activity as well as nitroxide radical scavenging activity on the 
surface of epidermal cells is inhibited by thioprotein inhibitors, 
anthralin, azelaic acid, and 13-cis-retinoic acid; activities are modu-
lated by calcium ions. It must be noted, however, that none of these 
are specific inhibitors for thioredoxin reductase. P-chloromercuri-
benzoate and dinitrochlorobenzene may inhibit various thiol me-
diated enzymic and non-enzymic reactions; azelacic acid inhibits 
several oxidoreductases [ 6]; anthralin is a strong reductant that has a 
complex redox chemistry and unspecifically influences many en-
zymes including oxidoreductases. 13-cis retinoic acid is known for 
its pleiotropic effects, and calcium ions affect many cell functions. 
In addition, Schal!reuter et al state in their synopsis that "this ni-
troxide radical substrate has been shown to be selectively reduced at 
the outer cell surface to a secondary amine" [7] and " furthermore 
the superoxide anion radical has been found to be a competitive 
substrate for nitroxide radical reduction" [7] . If one carefully reads 
the cited literature and all the recent papers. published b ' 
Schallreuter et al, their experimental data do not support these spe-
cific conclusions. 
Finally, Schallreuter eta! published two articles in 1986 [8,9] in 
which they report that their patented substrate, a cationic piperidin-
oxyl nitroxide [United States patent 4,849,346 (1989)] does not 
penetrate cell membranes more than 10% in 1 h . In their most 
recent synopsis paper [SJ they state that "A spin labeled analog of 
benzalkoniumbromide has been synthesized which does not pene-
trate the plasma membranes ofkeratinocytes, melanocytes, and mel-
anoma c~ll s" [9]. We reexami11ed these papers carefully but could 
not find m the text any evidence to support this claim. We chose 
instead to conduct experiments in liposomes, to demonstrate the 
permeability of different cationic nitroxides, including their pat-
ented nitroxide. In liposomes the data are not distorted by endoge-
nous nitroxide reduction that occurs in cells. Our experiments 
clearly showed that quarternary ammonium cations can diffuse 
thro~gh lipid bilayer membranes. Hence, the possibility must be 
constdered that for different cell types sites of intracellular reduc-
tion must be carefully evaluated. For these various reasons, we reit-
erate that assertions about "free radical reductase activity" in skin 
and the specificity of nitroxide based assays for these processes re-
quire careful reevaluation. 
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Differential Expression of Lymphocyte Function-Associated Antigen 1 
(LFA-1) on Epidermotropic and Non-Epidermotropic T-Cell Clones 
To the Editor: 
The article "Differential Expression of Lymphocyte Function-As-
sociated Antigen 1 (LFA-1) on Epidermotropic and Non-Epider-
motropic T -Cell Clones" by Shiohara and co-workers [1] states that 
" the presence of high levels ofLFA-1 on T cells is absolutely neces-
sary for their epidermotropic migration." 
However, two parts of the results speak against this statement. 
First, there is one clone (82F12) that expresses high levels ofLFA-1 
without being epidermotropic. Second, even in those clones that 
have phorbol ester induced expression ofLFA-1, there is no change 
from a non-epidermotropic to an epidermotropic state. Thus it is 
more likely that LFA-1 is not the molecule primarily involved in 
this experimental epidermotropism. Interestingly, there is also no 
information concerning the expression of ICAM-1, the ligand of 
LFA-1 on the epidermis of the foot-pads which would allow the use 
of this receptor ligand pair in epidermotropism. This could have 
been simply tested by staining with monoclonal antibodies against 
murine ICAM-1. 
It rather seems likely that other receptor ligand pairs are relevant 
for the observation of the authors because normal epidermis ex-
presses a wide variety of ligands belonging to various adhesion mol-
ecule families that would permit the entrance of T cells into the 
epidermis [2] . 
Wolfram Sterry, M.D. 
Department of Dermatology, University of Kiel 
Federal Republic of Germany 
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REPLY 
Dr. Sterry's comments regarding our recent paper [1] appear to 
contain a misapprehension of our observations and statement. Al-
though he did not mention the important findings of our previous 
study in his comments, we have clearly demonstrated that in vivo 
administration of monoclonal antibody (MoAb) to LFA-1 specifi-
cally blocks epidermotropic migration of cutaneous GVHD-pro-
ducing T cells and the subsequent destruction of the epidermis [2]. 
In addition, there is increasing experimental and clinical evidence to 
indicate that the receptor-ligand type interaction between LFA-1 on 
lymphocytes and ICAM-1 on keratinocytes serves a crucial role in 
adhesions of lymphocytes to epidermal keratinocytes [3,4]. Our 
findings that a close correlation between the density ofLFA-1 on T 
cells and the epidermotropic nature was observed in six clones of 
seven clones tested, together with the previous findings mentioned 
above, support the notion that the presence of high levels ofLFA-1 
on T cells is necessary for their epidermotropic migration. We do 
not state, however, that LFA-1 /1 CAM-1 interaction can be the only 
mechanism to explain the epidermotropism of certain T cells, be-
cause clone 82F12, despite high levels ofLFA-1 expression, is non-
epidermotropic. Thus, we are, of course, in agreement with the 
notion that adhesion molecules other than LFA-1 are also involved 
in epidermotropism of the T cells. However, his statement that 
adhesion molecules expressed by normal epidermis are involved in 
epidermotropism ofT cells seems unlikely. It does not make sense 
for the epidermis to normally express adhesion molecules that 
would allow the entry of leukocytes with ease. In order to protect 
the integrity of the epidermis from various unfavorable stimuli such 
as infection and trauma, this type of adhesion molecule should not 
be constitutively expressed, but be induced upon such stimuli on the 
keratinocytes. 
As mentioned briefly in the paper, it becomes clear that qualita-
tive, rather than quantitative, changes in LFA-1 expression are im-
portant for the regulation ofLFA-1- and ICAM-1-mediated leuko-
cyte adhesion [3,5]. Therefore, it is likely that up-regulation of 
LFA-1 with no increase in the avidity is not sufficient to trigger the 
epidermotropic migration. 
Because the mouse homologue of human ICAM-1 had not been 
identified at that time, and MoAb to human ICAM-1 such as RR1 /1 
did not cross-react to murine ICAM-1, it has remained to be deter-
mined whether ICAM-1 expression on keratinocytes is necessary 
for the epidermotropic migration of the T cells. Because a recent 
publication [6] showed that the murine lymphocyte activation anti-
gen MALA-2 is indistinguishable from human ICAM-1 in func-
tion, cellular distribution, and molecular properties, studies with 
the use of a rat MoAb to MALA-2 may provide direct evidence that 
LFA-1/ICAM-1 interaction is primarily involved in the epidermo-
tropic migration ofT cells. 
Tetsuo Shiohara, M.D., Ph.D. 
Masaji Nagashima, M.D., Ph.D. 
Department of Dermatology 
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